Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

BNOX

Bionomics Ltd. ADR

Dec 13 • 04:00PM ET

0.3231

Dollar change +0.0208
Percentage change 6.88	%

Healthcare • Biotechnology • Australia • NASD

Peers: BHVN FATE CORT NKTR ARWR KNSA CRSP AKRO BPMC QURE

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.94	Insider Own	-	Shs Outstand	17.32M	Perf Week	7.95%
Market Cap	5.60M	Forward P/E	-	EPS next Y	-0.42	Insider Trans	-	Shs Float	8.15M	Perf Month	10.35%
Income	-10.11M	PEG	-	EPS next Q	-	Inst Own	14.45%	Short Float	4.91%	Perf Quarter	-51.41%
Sales	0.00M	P/S	-	EPS this Y	65.83%	Inst Trans	-48.82%	Short Ratio	0.04	Perf Half Y	-58.58%
Book/sh	0.99	P/B	0.33	EPS next Y	31.58%	ROA	-42.49%	Short Interest	0.40M	Perf Year	-71.41%
Cash/sh	0.47	P/C	0.69	EPS next 5Y	-	ROE	-59.91%	52W Range	0.18 - 1.60	Perf YTD	-78.17%
Dividend Est.	-	P/FCF	-	EPS past 5Y	14.53%	ROI	-58.91%	52W High	-79.81%	Beta	0.27
Dividend TTM	-	Quick Ratio	3.30	Sales past 5Y	-58.75%	Gross Margin	-	52W Low	82.54%	ATR (14)	0.05
Dividend Ex-Date	-	Current Ratio	3.30	EPS Y/Y TTM	64.09%	Oper. Margin	-	RSI (14)	54.12	Volatility	13.18% 12.86%
Employees	24	Debt/Eq	0.01	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	4.00
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	-	Payout	-	Rel Volume	0.20	Prev Close	0.30
Sales Surprise	2.23%	EPS Surprise	-2.22%	Sales Q/Q	-	Earnings	Aug 21	Avg Volume	9.52M	Price	0.32
SMA20	10.42%	SMA50	11.92%	SMA200	-52.63%	Trades		Volume	1,917,436	Change	6.88%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-28-23	Upgrade	H.C. Wainwright	Neutral → Buy	$8
Sep-28-23	Reiterated	Maxim Group	Buy	$7 → $10
Jan-10-22	Initiated	H.C. Wainwright	Buy	$54
Jan-10-22	Initiated	Evercore ISI	Outperform	$17
Jan-10-22	Initiated	Cantor Fitzgerald	Overweight	$52
Jan-10-22	Initiated	Berenberg	Buy	$21

Dec-12-24 04:05PM	Results of Scheme Meeting (GlobeNewswire) +5.29% +6.88%
Dec-09-24 08:00AM	Bionomics Publishes the Positive Results from the Phase 2 ATTUNE Study of BNC210 in Patients with Post-Traumatic Stress Disorder in NEJM Evidence (GlobeNewswire)
Dec-03-24 04:05PM	Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting (GlobeNewswire) -6.56%
Dec-02-24 05:01PM	Bionomics Reminds Shareholders to Cast their Vote for Re-Domiciliation from Australia to the United States (GlobeNewswire)
Nov-08-24 04:15PM	Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement (GlobeNewswire) +6.53% -9.12%
08:00AM	Loading…
Nov-07-24 08:00AM	Bionomics to Present at the 2024 CNS Summit (GlobeNewswire) +36.25%
Nov-04-24 04:15PM	Bionomics Receives Milestone Payment of AUS$1M from Carina Biotech for BNC101 Partnered Legacy Oncology Program (GlobeNewswire) +157.79%
Oct-23-24 06:00AM	Bionomics to Present at the ThinkEquity Conference (GlobeNewswire)
Oct-14-24 08:00AM	Bionomics to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC (GlobeNewswire) -6.82%
Oct-08-24 08:50AM	Bionomics CEO believes company has significant, unrealized value (TipRanks)
Oct-07-24 08:00AM	Bionomics Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision (GlobeNewswire)
Oct-01-24 06:30AM	Bionomics Limited announces intention to re-domicile to the United States (GlobeNewswire) -11.20%
Sep-03-24 06:30AM	Bionomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Jul-31-24 06:30AM	Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder (GlobeNewswire) -9.78%
Jul-29-24 04:30PM	Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024 (GlobeNewswire) +24.01%
06:30AM	Loading…
Jul-18-24 06:30AM	Bionomics Initiates AFFIRM-1, a Phase 3 Clinical Trial with BNC210 for Social Anxiety Disorder (GlobeNewswire)
May-31-24 08:00AM	Bionomics Limited Announces Private Placement of up to $70.0 Million (GlobeNewswire) -14.97%
May-20-24 06:30AM	Bionomics to Present at the 2024 American Society of Clinical Psychopharmacology Annual Meeting (GlobeNewswire)
Mar-21-24 06:00AM	Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (GlobeNewswire)
Feb-22-24 04:30PM	Bionomics to Present at the 2024 BIO CEO & Investor Conference (GlobeNewswire) -8.00%
Feb-05-24 03:11AM	10 Best Australian Stocks To Buy (Insider Monkey)
Feb-04-24 11:01AM	7 Strong Buy Stocks Under $20: February 2024 (InvestorPlace)
Jan-22-24 06:00AM	Bionomics Provides a Review of 2023 and of 2024 Plans (GlobeNewswire)
Jan-05-24 06:00AM	Bionomics to Present at Biotech Showcase 2024 (GlobeNewswire)
Dec-06-23 08:00AM	Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting (GlobeNewswire) +5.08%
Oct-30-23 02:02PM	12 Best Stocks For Day Trading (Insider Monkey)
Oct-16-23 08:00AM	Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder (GlobeNewswire) +14.18%
Sep-29-23 08:51AM	Bionomics (BNOX) Meets Goals in PTSD Study, Stock Rallies 244% (Zacks) -19.88%
12:13AM	Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD) (PR Newswire)
Sep-28-23 08:03AM	Why Is Bionomics (BNOX) Stock Up 347% Today? (InvestorPlace) +242.13%
07:09AM	Loading…
07:09AM	Bionomics' midphase PTSD trial hits primary endpoint, briefly tripling its battered share price (FierceBiotech.com)
06:00AM	Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD) (GlobeNewswire)
Sep-14-23 06:00AM	Bionomics Announces Update on the 7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD (GlobeNewswire) -25.14%
Aug-24-23 11:50AM	Bionomics (BNOX) Up on Positive Updates on PTSD & SAD Candidate (Zacks) +7.91%
Aug-23-23 06:00AM	Bionomics Completes Last Patient Last Visit in the Phase 2b ATTUNE Study for Post-Traumatic Stress Disorder (PTSD) and Confirms Expected 2023 Milestones with its Lead Asset BNC210 (GlobeNewswire) +15.83%
Jul-31-23 06:00AM	Quarterly Activities and Cashflow Report (GlobeNewswire) -14.14%
Jul-25-23 06:00AM	Bionomics Announces Intention to Delist from the Australian Securities Exchange (ASX) (GlobeNewswire) -15.93%
Jul-15-23 08:27PM	Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jul-03-23 06:00AM	Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth (GlobeNewswire) +5.95%
Jun-15-23 08:00AM	Bionomics to Present at Upcoming June Investor Conferences (GlobeNewswire)
May-30-23 06:00AM	Bionomics Announces Upcoming Poster Presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting (GlobeNewswire) -5.62%
Apr-28-23 06:00AM	Quarterly Activities and Cashflow Report (GlobeNewswire)
Apr-27-23 06:00AM	Bionomics Announces the Completion of Enrollment in Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD) (GlobeNewswire)
Mar-09-23 10:54AM	Bionomics Reveals Detailed Data From Its Flunked Anxiety Trial, Shows Reductions In Anxiety Across Multiple Phases (Benzinga) -26.24%
Mar-08-23 07:00PM	Bionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD) (GlobeNewswire) +7.39%
Mar-03-23 09:55AM	Bears are Losing Control Over Bionomics Limited Unsponsored ADR (BNOX), Here's Why It's a 'Buy' Now (Zacks)
Feb-24-23 03:05PM	Bionomics First Half 2023 Earnings: AU$0.012 loss per share (vs AU$0.013 loss in 1H 2022) (Simply Wall St.) +19.03%
Feb-23-23 06:00AM	Bionomics Half-Year Report (GlobeNewswire) +9.47%
Feb-05-23 07:02PM	Will Bionomics (ASX:BNO) Spend Its Cash Wisely? (Simply Wall St.)
Jan-30-23 06:23PM	Quarterly Activities and Cashflow Report (GlobeNewswire) -6.20%
Dec-19-22 03:29PM	All Focus Shifts To Bionomics' PTSD Study After Anxiety Trial Disappoints (Benzinga) -13.38%
09:30AM	Bionomics' Social Anxiety Disorder Study Fails To Meet Primary Endpoint (Benzinga)
Dec-18-22 07:34PM	Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder (GlobeNewswire)
Dec-15-22 06:35PM	Bionomics appoints Spyridon Spyros Papapetropoulos as President and Chief Executive Officer (GlobeNewswire)
Dec-02-22 06:00AM	Bionomics Announces Accepted Abstract and Upcoming Poster Presentations at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting (GlobeNewswire)
Nov-21-22 06:13PM	Bionomics Limited Announces Closing of US$5 Million Underwritten Offering of American Depositary Shares in the United States (GlobeNewswire)
Nov-16-22 06:36PM	Bionomics Limited Announces Pricing of Underwritten Offering of American Depositary Shares in the United States (GlobeNewswire) -17.41%
Nov-02-22 06:00AM	Bionomics Limited to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-25-22 06:00AM	Quarterly Activities Report for September 2022 (GlobeNewswire)
Oct-18-22 06:00AM	Bionomics Receives R&D Tax Incentive Refund for FY2022 of A$4.6 million (GlobeNewswire)
Oct-07-22 04:39PM	Bionomics (ASX:BNO) adds AU$20m to market cap in the past 7 days, though investors from five years ago are still down 84% (Simply Wall St.)
Oct-04-22 06:00AM	Bionomics Limited to Participate in the Cantor Neurology & Psychiatry Conference (GlobeNewswire)
Sep-21-22 06:00AM	Bionomics to Host KOL Webinar on BNC210 and Social Anxiety Disorder (GlobeNewswire)
Sep-15-22 09:55AM	Can Bionomics Limited Unsponsored ADR (BNOX) Climb 329% to Reach the Level Wall Street Analysts Expect? (Zacks)
Aug-31-22 06:00AM	Bionomics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-30-22 09:55AM	Does Bionomics Limited Unsponsored ADR (BNOX) Have the Potential to Rally 329% as Wall Street Analysts Expect? (Zacks)
Aug-27-22 06:26PM	We're Keeping An Eye On Bionomics' (ASX:BNO) Cash Burn Rate (Simply Wall St.)
Aug-25-22 06:00AM	Bionomics reports Full Year Financial Results (GlobeNewswire) +7.42%
Aug-08-22 06:00AM	Bionomics Receives R&D Tax Incentive Refund for FY2021 of A$2.1M (GlobeNewswire)
Jul-29-22 06:00AM	Quarterly Activities Report for June 2022 (GlobeNewswire)
Jul-08-22 06:00AM	Bionomics to Participate in William Blairs Biotech Focus Conference 2022 (GlobeNewswire) +8.82%
Jun-27-22 06:00AM	Bionomics Limited to Participate in the H.C. Wainwright Mental Health Conference (GlobeNewswire)
Jun-24-22 07:44AM	Fewer Investors Than Expected Jumping On Maxim Power Corp. (TSE:MXG) (Simply Wall St.)
Jun-13-22 04:30PM	Bionomics Investor Webinar (GlobeNewswire) -14.02% +5.62%
May-16-22 06:00AM	Bionomics Limited to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-10-22 08:00AM	Novamind to Host Bionomics PREVAIL Trial for Acute Treatment of Social Anxiety Disorder (ACCESSWIRE)
Feb-23-22 09:00PM	Bionomics' Half-Year Report (GlobeNewswire)
Jan-14-22 07:06AM	Bionomics Limited (Nasdaq: BNOX, ASX: BNO) to Ring the Nasdaq Stock Market Closing Bell on Friday January 14, 2022 (PR Newswire)
Jan-12-22 06:00AM	Bionomics Limited participated in the H.C Wainwright BioConnect Conference (PR Newswire)
Jan-05-22 05:58PM	Bionomics Limited Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs in the United States (PR Newswire)
Jan-03-22 06:00AM	Bionomics Initiates Phase 2 PREVAIL Study of BNC210 for the Acute Treatment of Social Anxiety Disorder (PR Newswire)
Dec-16-21 06:00AM	Bionomics Limited Announces Pricing of Initial Public Offering in the United States (PR Newswire)

Bionomics Ltd. is a clinical stage biopharmaceutical company, which develops novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need. Its lead product candidate is BNC210. The company was founded in 1996 and is headquartered in Eastwood, Australia.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BNOX

Bionomics Ltd. ADR

Upgrade your FINVIZ experience